Why this article exists
NAD+ has become one of those terms — like collagen, like leaky gut, like adrenal fatigue — where the public conversation has outrun the clinical evidence in a way that makes a careful physician slightly uncomfortable. National outlets ran skeptical pieces this spring, including the May 11 NPR story on whether NAD+ infusions and supplements actually move the longevity needle. The honest answer, then and now, is that the route matters and the data tiers are genuinely uneven.
This article is the route-by-route read. It covers what the precursor RCTs — primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — actually show on durable endpoints. It covers what the IV route does pharmacokinetically, where the controlled data are missing, and why the IV loading protocol still earns its place in the Limitless menu. And it covers what a physician should actually tell a prospective patient who has read the NPR piece — without abandoning the protocol or pretending the criticism is illegitimate.
What the precursor RCTs actually show
The oral NR and NMN trial base has been the more substantively studied side of the NAD+ space. By 2026, the picture across the precursor literature is consistent enough to summarize cleanly. NR and NMN reliably raise whole-blood NAD+ levels. They are tolerated at the doses studied. The downstream clinical effects are smaller and more variable than the marketing implies — modest improvements in muscle insulin sensitivity in postmenopausal women on NMN, a small blood-pressure reduction in older adults on NR, modest improvements in fatigue, and signal-generating but not definitive work in muscle strength.
The newest entry in this picture is a double-blind, randomized, crossover trial published in npj Aging on a multi-ingredient "systems" NAD+ supplement. The trial reported a clear increase in whole-blood NAD+, a rise in SIRT1, a reduction in pro-inflammatory cytokines, and a shift in IgG glycosylation patterns toward a younger biological age signature. That is the most useful piece of new precursor data in some time — and we cite it explicitly because it is exactly the kind of mechanistically coherent, biomarker-anchored RCT result that the NAD+ space has been short of.
What none of these precursor trials have produced is a hard-endpoint demonstration of slowed aging, reduced mortality, reduced incident dementia, or any of the longevity claims that vendor pages routinely imply. The 2026 PRISMA systematic review of more than 100 NAD+ studies says exactly that: biological activity is clear, anti-aging clinical effectiveness remains inconclusive. The 2025 Nature Aging expert review — written by 25 senior investigators in the field — said the same thing in calmer language.
What the IV route is and is not
The IV NAD+ route does not have the precursor RCT base behind it. There is no large randomized trial of IV NAD+ infusion in healthy adults with a hard-endpoint outcome, and very limited published controlled data on IV NAD+ in any setting. That is the legitimate part of the skepticism. We acknowledge it on the main NAD+ evidence page and we repeat it here.
What the IV route does have is unambiguous pharmacokinetics. IV NAD+ raises serum NAD+ rapidly and to levels not achievable with oral precursor dosing. The published Frontiers retrospective pilot of IV NAD+ versus NR tolerability, published in 2026, is the first controlled comparison aimed directly at our question — and its main finding is that the IV route delivers reliable rises with a flushing/tolerability signature that is well-managed by drip-rate control. The pilot is not a longevity-endpoint trial. It is, however, an honest tolerability benchmark in the kind of patients who actually receive IV NAD+ in practice, and the only piece of comparative data of its kind in 2026.
So the route comparison is asymmetric in a specific way. The precursors have moderate RCT evidence for biomarker movement and small clinical effects. The IV route has unambiguous pharmacokinetic data, a published tolerability comparison, and a real absence of large hard-endpoint trials. Neither route has earned a longevity claim. Both routes do things to a patient's NAD+ metabolism that are worth doing inside an evidence-honest framework.
Why the Limitless protocol leads with the IV load
The standing Limitless NAD+ protocol is unchanged by the 2026 data: a 5 × 750 mg IV loading series over the first two weeks, followed by 100–200 mg SubQ maintenance daily or every other day. The reasoning is not that IV is better than oral. The reasoning is that the IV load is the route most likely to produce a discriminating clinical signal in the patient's own experience — energy, sleep depth, recovery — within the window of a loading series, and the SubQ maintenance step is the bridge from that loading signal to a sustained intake that does not require infusion logistics.
For a patient whose preference is oral, or whose situation makes infusion impractical, the Limitless posture is to substitute oral NR or NMN, frame the evidence honestly, and skip the IV step. The protocol is a sequence; the molecule is the same NAD+ biology either way; the route is selected with the patient, not for them. See the IV experience guide for what the loading series actually feels like and how the flush and drip rate are managed.
What the NPR piece got right — and what it didn't
The May 11 NPR piece quoted serious researchers, and the central point is correct: NAD+ marketing has outrun the clinical evidence. It is right to highlight that. It is also a narrower point than the headline suggests. What the piece did not do — because it was a 1,200-word general-audience article rather than a clinical review — is distinguish the mechanism (settled), the precursor RCT base (moderate and growing), and the IV pharmacokinetic data (real, under-trialed) from each other. Lumping all three together produces a story that reads as "this whole space is hype." That is the unfair part.
The fair reading is the one this site has used since the original NAD+ evidence brief. There is a real biology here. The precursor RCTs say modest things, modestly, on plausible biomarker endpoints. The IV pharmacokinetic data is what it is. None of it justifies a "fountain of youth" claim. All of it justifies a careful, monitored, transparently-framed protocol in patients who understand what the evidence does and does not say.
The evidence, by route
| Route | Evidence tier | Position at Limitless |
|---|---|---|
| Oral NR / NMN precursors | Multiple RCTs; biomarker movement clear; modest clinical effects; npj Aging 2026 crossover adds SIRT1 + glycosylation signal | Substitute for IV when the patient prefers oral or infusion is impractical. Disclosed clearly. |
| IV NAD+ infusion | Unambiguous PK; Frontiers 2026 retrospective tolerability pilot; no large hard-endpoint RCT | Limitless loading-series lead — 5 × 750 mg over two weeks, drip-rate-managed. |
| SubQ NAD+ maintenance | Pharmacokinetic data; clinical literature smaller than IV | Bridge from the IV loading series — 100–200 mg daily/EOD, unchanged by the 2026 data. |
| Anti-aging / longevity-endpoint claim (any route) | No hard-endpoint human RCT exists in 2026 | Not claimed. Said out loud on every page. |
How the 2026 data changes prescribing — it doesn't
The route is chosen with the patient, the framing is unchanged.
The Limitless NAD+ protocol remains: 5 × 750 mg IV loading series over the first two weeks, then 100–200 mg SubQ maintenance daily or every other day. For patients who prefer oral, NR or NMN is substituted at evidence-appropriate doses and the IV step is skipped. The protocol is not changing because of the Frontiers tolerability pilot or the npj Aging crossover RCT; if anything, both add evidence-aligned reasons to keep doing what we already do.
The framing is unchanged. Mechanism solid, precursor RCT data moderate and growing, IV pharmacokinetics real and under-trialed, longevity-endpoint claim not made. We will repeat that any time a patient mentions a news cycle, a vendor page, or a podcast.
Foundations first, always. NAD+ is one input into a larger longevity protocol that begins with sleep, training, nutrition, and indicated hormone optimization — not a replacement for any of them.
What we tell every NAD+ patient
- The mechanism — falling NAD+ with age, restoration via precursor or IV — is biochemically real.
- The precursor RCT data is the strongest part of the NAD+ literature. The npj Aging 2026 systems-NAD+ crossover is the cleanest recent addition.
- The IV route has unambiguous pharmacokinetics and a 2026 controlled tolerability pilot. It does not yet have a large hard-endpoint trial.
- No NAD+ product or route has demonstrated longer life expectancy in a randomized trial. Anything that says otherwise is marketing.
- The Limitless loading-series + maintenance protocol is designed around what the evidence does support — biomarker movement, pharmacokinetic load, and a discriminating patient-experience window — not around the claims it does not.
- If you have read a skeptical article and want to discuss it, that is the conversation we want to have. The honest version is on this page.
What updates this article
This article will update when a hard-endpoint randomized trial of IV NAD+ in adults is published, when the precursor (NR/NMN) trial base extends into mortality or incident-disease endpoints, when the Frontiers tolerability pilot is extended into a larger comparison, and whenever the NAD+ regulatory or evidence picture shifts materially. The standing posture in the box above governs every Limitless NAD+ prescription as of 2026-05-26.